Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. KPS≥70~2. Diagnosis of pathologically positive lymph node thoracic esophageal cancer~3. Complete resection~4. Adequate organ function:~Hematopoietic Absolute granulocyte count at least 1,500/mm\^3 Platelet count at least 150,000/mm\^3 Hemoglobin at least 10 g/dL Hepatic Not specified Renal Creatinine no greater than 1.5 mg/dL AND/OR Creatinine clearance at least 65 mL/min Calcium no greater than 11 mg/dL Cardiovascular No uncontrolled heart disease No uncontrolled hypertension~Exclusion Criteria:~1. Uncontrolled diabetes~2. Interval between surgery and adjuvant therapy more than 3 months~3. Sign of recurrence on CT scan or ultrasound or PET-CT No palpable supraclavicular lymph nodes or involvement after cytology needle aspiration No lymph nodes greater than 1 cm on CT scan~4. With Weight loss greater than 10% from baseline~5. With other prior or concurrent malignancy except basal cell skin cancer or carcinoma in situ of the cervix~6. Be pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): During the Phase I it will administered weekly paclitaxel(dose escalation) and cisplatin with concurrent radiation therapy~During the Phase II it will administered weekly paclitaxel(dose according to phase I) and cisplatin with concurrent radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).